2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
21
Carcinoma, Transitional Cell
17
Anus Neoplasms
17
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
11
Appendiceal Neoplasms
11
Stomach Neoplasms
10
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Urologic Neoplasms
4
Sarcoma
4
Carcinoma
4
Anal Canal Carcinoma
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Recurrence
3
Pseudomyxoma Peritonei
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Interventions
fluciclovine F-18
2
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Sunitinib
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled